Venetoclax inhibits BCL-2 (BH3 mimetic), relieving its anti-apoptotic block and enabling BAX/BAK–mediated mitochondrial outer-membrane permeabilization, cytochrome c release, and caspase activation, causing intrinsic apoptosis in BCL-2–dependent cells.